Results 101 to 110 of about 210,637 (269)

Single-dose GnRH agonist administration in the luteal phase of GnRH antagonist cycles: a prospective randomized study [PDF]

, 2009
This study was designed to evaluate the effect of luteal-phase administration of single-dose gonadotrophin-releasing hormone (GnRH) agonist on pregnancy, implantation and live birth rates in patients who received GnRH antagonist for pituitary ...
Vicdan, Kubilay, Işık, Zeki, Çağlar, Gamze Sinem, Sözen, Eran, Akarsu, Cem, Özbiçer, Tülay, Tuncay, Görkem, A.Z. Isik, E. Sozen, T. Ozbıcer, C. Akarsu, G. Tuncay, G.S. Caglar, K. Vicdan   +13 more
core   +1 more source

Diabetes‐Induced Testicular Injury: Potential Protective Roles of Curcumin, Garcinia kola, and Momordica charantia in Rats

Andrology, EarlyView.
ABSTRACT Background Diabetes mellitus (DM) induces multifaceted cellular and structural alterations in the male reproductive system, thereby predisposing to infertility. Objectives This study aimed to evaluate the morphological, stereological, biochemical, histopathological, and ultrastructural changes induced by DM in testicular tissue, and to ...
Ayşenur Kaya Mutlu, Süleyman Kaplan
wiley   +1 more source

Progestin-Primed Ovarian Stimulation versus GnRH Antagonist Protocol for Ovarian Stimulation in IVF: A Prospective Pilot Study

Fertility & Reproduction
Background: Progestin-primed ovarian stimulation (PPOS) has been proposed as an alternative to conventional gonadotropin-releasing hormone (GnRH) antagonist protocol for ovarian stimulation in in vitro fertilization (IVF).
Tien K. Le, Xuyen H. Le, Duy L. Nguyen, Anh L. Vu, Lan N. Vuong   +4 more
doaj   +1 more source

Usefulness of combined androgen blockade therapy with gonadotropin-releasing hormone antagonist for bone metastatic prostate cancer with pretreatment prostate-specific antigen level ≥ 50 ng/mL

BMC Cancer, 2018
Background This study was performed to examine the usefulness of combined androgen blockade (CAB) therapy with a gonadotropin-releasing hormone (GnRH) antagonist (CAB-antagonist therapy), instead of CAB therapy with GnRH agonist (CAB-agonist therapy ...
Takeshi Kashiwabara, Sayo Suda
doaj   +1 more source

Long-term effects of GnRH agonist, GnRH antagonist, and estrogen plus progesterone treatment on apoptosis related genes in rat ovary.

, 2009
Objective: To define the long-term effects of GnRH antagonist, GnRH agonist, and estrogen plus progesterone treatments on apoptosis and apoptosis-related gene expressions, including bcl2, bax, and cyt c in rat ...
POSACI, CEMAL, ULUKUŞ, EMİNE ÇAĞNUR, KIZILDAĞ, SEFA, Atabey, Nese, KOYUNCUOĞLU ÜLGÜN, MERAL, Saatli, Bahadir, Dogan, Erbil   +6 more
core   +1 more source

Prospective Short‐ and Long‐Term Changes in Cardiometabolic Risk Markers Following Gender‐Affirming Hormone Therapy

Andrology, EarlyView.
ABSTRACT Introduction Gender‐affirming hormone therapy (GAHT) may be associated with increased cardiometabolic disease (CMD) risk. Prospective CMD risk screening is recommended, but long‐term data are needed regarding changes in CMD markers. Objectives To evaluate prospective changes in CMD risk markers during GAHT.
Louise Lehmann Christensen, Camilla Viola Palm, Marianne S. Andersen, Guy T'Sjoen, Jan Frystyk, Tine Taulbjerg Kristensen, Rikke Hjortebjerg, Dorte Glintborg   +7 more
wiley   +1 more source

Evaluation of the effects of gonadotropin-relasing hormone antagonist (GnRH-ant) and agonist (GnRH-a) in the prevention of postoperative adhesion formation in a rat model with immunohistochemical analysis

, 2011
Objective: To investigate the effects of GnRH antagonist (GnRH-ant) and agonist (GnRH-a) in the prevention of postoperative pelvic adhesions by a visual scoring system and immunohistochemical methods in a rat uterine horn ...
Tamay, Asli Goker, Koltan, Semra Oruc, Semra Oruc Koltan, Koyuncu, Faik Mumtaz, CİLAKER MIÇILI, SERAP, Yildirim, Yasemin, Serap Cilaker Micili, Yasemin Yildirim, Asli Goker Tamay, Faik Mumtaz Koyuncu, Tevfik Guvenal, Candan Ozogul, GÜVENAL, Tevfik, ÖZOĞUL, CANDAN   +13 more
core   +1 more source

The Impact of Common Medications on Male Fertility: An Updated Systematic Review

Andrology, EarlyView.
ABSTRACT Background Compared with those of cytotoxic treatments, the potential effects of common medications on the fertility of men trying to conceive currently or planning to conceive in the future are less well described. The use of common medications may modify the gonadotropic axis, spermatogenesis, and epididymal maturation or alter male ...
Lina Jebli, Salomé Gallissian, Roxanne Barèges, Félicia Fournier, Catherine Metzler‐Guillemain, Ségolène Prades, Fanny Magnan‐Sebag, Jeanne Perrin   +7 more
wiley   +1 more source

GnRH agonist and GnRH antagonist protocols: comparison of outcomes among good-prognosis patients using national surveillance data

, 2014
Implantation and live birth rates resulting from IVF cycles using gonadotropin-releasing hormone (GnRH) agonist and (GnRH) antagonist IVF protocols were compared among good-prognosis patients using the Centers for Disease Control and Prevention\u27s ...
Grow, Daniel, MD
core   +1 more source

GnRH antagonist versus agonist in normoresponders undergoing ICSI: a randomized clinical trial in Iran [PDF]

, 2012
Background: General concern is that the pregnancy rate is higher with GnRH-agonist as a protocol of pituitary suppression. GnRH-antagonist protocol provides a shorter period of administration and an easy flexible protocol.
Nekoo, Elham Azimi, Nezamabadi, Akram Ghahghaei, Jafarabadi, Mina, Tehraninejad, Ensieh, Rashidi, Batool, Sohrabi, Maryam, Bagheri, Maryam, Haghollahi, Fedyeh   +7 more
core